PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Mazdutide

IBI362; LY3305677

Classification: GLP-1/glucagon dual agonist

Mechanism: Oxyntomodulin analog; activates GLP-1 and glucagon receptors

Benefits: Weight loss; glycemic control; hepatic fat reduction (Phase 2/3 China)

Evidence tier: Phase 3 (China) · Availability: Investigational

Primary sources

  1. Ji L et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun 2023. PMID 38092790
  2. Ji L et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1). N Engl J Med 2025. PMID 40421736

Loading interactive view…